{
    "2019-07-23": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Biogen downplays ‘premature’ talk of competition for SMA drug Spinraza",
                "features": {
                    "keywords": [
                        "Biogen",
                        "downplays",
                        "competition",
                        "SMA drug",
                        "Spinraza"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Biogen’s Good Quarter Delays Drugmaker’s Future Reckoning",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Good Quarter",
                        "Delays",
                        "Future Reckoning"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Biogen’s Earnings Beat Forecasts, but 1 Key Drug Fell Short",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Earnings Beat",
                        "Forecasts",
                        "Key Drug",
                        "Fell Short"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Abbott",
                        "Netflix",
                        "Philip Morris",
                        "United Technologies",
                        "Novartis"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diverse sectors"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}